Short-term use of gonadotropin-releasing hormone agonist (Leuprolide) for in vitro fertilization
- 1 December 1988
- journal article
- conference paper
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 5 (6) , 332-334
- https://doi.org/10.1007/bf01129568
Abstract
A common problem encountered by in vitro fertilization (IVF) programs is the premature occurrence of the spontaneous lutenizing hormone (LH) surge during ovarian stimulation cycles. Administration of gonadotropin-releasing hormone agonists (GnRH-a) for 2 to 3 weeks produces a state of hypogonadotropic hypogonadism, thus allowing ovarian stimulation to proceed uncomplicated by a spontaneous LH surge. We have elected to treat seven patients with GnRH-a in a “short-term” protocol, with GnRH-a initiated on cycle day 3 along with exogenous gonadotropins. In this series, we found that the spontaneous LH surge was abolished, while ovarian responsiveness seemed to be improved. These results suggest that the initial surge of gonadotropins elicited by GnRH-a administration may enhance ovarian stimulation and that spontaneous LH surge is blocked when GnRH-a and exogenous gonadotropins are initiated concomitantly.This publication has 4 references indexed in Scilit:
- Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilizationFertility and Sterility, 1987
- INDUCTION OF OVULATION FOR IN-VITRO FERTILISATION USING BUSERELIN AND GONADOTROPINSThe Lancet, 1984
- Medical hypophysectomy: I. Dose-response using a gonadotropin-releasing hormone antagonistFertility and Sterility, 1984
- Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phaseFertility and Sterility, 1983